Ipsen will own exclusive worldwide rights on any candidate
recombinant toxin resulting from the collaboration, while Harvard will earn associated upfront, milestones and royalty payments.
Keywords:
Recombinant toxin; Biopesticides; Insect resistance; Multiple genes; Insecticidal proteins; Spider toxin
Also, Ipsen will have exclusive worldwide rights on any candidate
recombinant toxin stemming from the collaboration and will be responsible for the development and marketing of the new toxins and will make associated upfront, milestones and royalty payments to Harvard.